ClinicalTrials.gg
CompletedNCT01705223Updated May 6, 2015

Safety and Immunogenicity Study of AIDS Vaccine (Combined Use of DNA Vaccine and Recombinant Vaccinia Virus Tiantan)

A Phase 2 interventional study of DNA vaccine and DNA vaccine prime with the addition of electroporation in AIDS, sponsored by National Center for AIDS/STD Control and Prevention, China CDC. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-05-06.

Sponsored by National Center for AIDS/STD Control and Prevention, China CDC · Phase 2, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 87 studies in Acquired Immunodeficiency Syndrome with a site in China — 21 open to participants now, 24 under way, 1 of them phase 3. Acquired Immunodeficiency Syndrome · China.

Enrollment
29th of 68
150 · median 108
Started
2012
with 3 others
Phase 2
7 of 87
none open now
Registered
15th of 87
by date
Lead sponsor
6 of 87
National Center for AIDS/STD Control and Prevention, China CDC

Among the 87 studies in Acquired Immunodeficiency Syndrome with a site in China, this one is the 29th largest by enrollment of the 68 interventional ones that give a count, is one of 4 that started in 2012, is one of 7 in phase 2, and was the 15th registered.

Acquired Immunodeficiency Syndrome

3,039 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

Browse Acquired Immunodeficiency Syndrome studies →

Open to participants now

21 of the 87 studies in Acquired Immunodeficiency Syndrome with a site in China are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 197 Acquired Immunodeficiency Syndrome studies recruiting now, 117 (59%) set no upper age limit and 67 (34%) stop at 75 or younger; 43 take children under 18; 68 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies in Acquired Immunodeficiency Syndrome with a site in China, or all of them as a file.
02

Study summary

This trial studies the safety and immunogenicity of a HIV clade B'/C DNA vaccine followed by recombinant vaccinia virus rTV boost in HIV-uninfected healthy volunteers at low or high risk of HIV infection. In addition, the effect of different intervals of the prime-boost will be studied.

03

Conditions studied

  • AIDS

Keywords

  • prophylactic
  • vaccine
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing to be followed for the planned duration of the study, and receive intravenous blood collection and sample storage in the 16\~20 months after first vaccination;
  • Understand and agree with the content of ;
  • Volunteers at low risk of infection, or high-risk men who have sex with men (MSM), who had have oral sex or anal sex with another man in the past 6 months ;
  • Willing to be tested for HIV and syphilis;
  • Before 2 weeks of the first vaccination and after 12 months of the last vaccination, willing to use an effective method of with sexual partner. Female subjects are willing to undergo urine pregnancy test before each vaccination and at the follow-up visit.

Exclusion criteria

Exclusion Criteria:

  • Have close contact with people who are pregnant or lactating in the one month after vaccination of rTV vaccine;
  • Have listed diseases or medical history:

    • Have innate or acquired immune deficiency disease or have close contact with patients suffering from the above-mentioned diseases within 1 month of rTV vaccination;
    • Need treatment affecting immunization, e.g. use for more than 2 weeks or use immunosuppressives, e.g. alkylating, anti-metabolite or radiotherapy, etc.; or have close contact with patients suffering from the above-mentioned diseases within 1 month of rTV vaccination;
    • Suffering from diseases such as cancer, organ or stem cell transplants, non-agammaglobulinemia, etc.; or have close contact with patients suffering from the above-mentioned diseases within 1 month of rTV vaccination;
    • Past or current suffering from eczema or atopic dermatitis; currently suffering from diseases that cause skin damage such as: burns, scald, chicken pox, impetigo, shingles, psoriasis, etc.; or have close contact with patients suffering from the above-mentioned diseases within 1 month of rTV vaccination;
    • Past or current high blood pressure, heart disease, diabetes, thyroid disease, asthma, angioedema, asplenia syndrome, mental illness, epilepsy, severe anemia, leukopenia and thrombocytopenia, etc.;
    • History of syncope after vaccination or allergies;
    • Currently suffering from acute infectious diseases and febrile diseases;
  • The following circumstances are:

    • received within 2 months or other vaccine within 2 weeks prior to enrollment;
    • Immunoglobin or blood products received within 4 months prior to enrollment;
    • Participation in another trial of a medicinal product, completed less than 30 days prior to enrollment;
    • Drug abuse, alcoholism, heavy smokers;
  • The following laboratory test abnormalities, except for the results that are assessed by researchers as being no clinical significance:

    • diagnostic assay positive or suspicious, HIV RNA diagnostic assay positive;
    • Anti-DNA antibody or anti-nuclear antibody positive;
    • Other laboratory test abnormalities;
  • Not complying with study protocol or not obtaining because of medical, spiritual, social, occupational, and/or other reasons.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    group A

    DNA vaccine prime at week 0,4,8 and rTV boost at week 16

    Biological: DNA vaccine · Biological: rTV boost

  • Experimental
    group B

    DNA vaccine prime at week 0,4,8 and rTV boost at week 24

    Biological: DNA vaccine · Biological: rTV boost

  • Experimental
    group C

    DNA vaccine prime at week 0,4,8 and rTV boost at week 32

    Biological: DNA vaccine · Biological: rTV boost

  • Experimental
    group D

    DNA vaccine prime with the addition of electroporation at week 0, 4, 8 and rTV boost at week 24

    Biological: DNA vaccine prime with the addition of electroporation · Biological: rTV boost

Interventions

  • BiologicalVaccines, DNAStudies of Vaccines, DNAVaccines, DNA pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    4mg/dose, three doses at week 0,4,8

  • BiologicalDNA vaccine prime with the addition of electroporation

    4mg/dose, three doses at week 0,4,8

  • BiologicalrTV boost

    at week 16

  • BiologicalrTV boost

    at week 24

  • BiologicalrTV boost

    at week 32

06

What researchers measure

Primary outcomes

  1. Occurrence, intensity and relationship to vaccination of local and general adverse events

    Time frame: 14-day follow-up after DNA vaccine vaccination

  2. Occurrence and relationship to vaccination of any serious AEs (SAEs)

    Time frame: During the study period (Month 0-20)

  3. Occurrence, intensity and relationship to vaccination of clinically significant abnormal haematology and biochemistry values (grade 4)

    Time frame: During the study period (Month 0-20)

  4. test HIV specific T cell response by ELISPOT

    Time frame: 2wk, 4wk, 14wk, 24wk after rTV vaccination

  5. test HIV specific antibody by ELISA

    Time frame: 2wk, 4wk, 14wk, 24wk, 48wk after rTV vaccination

  6. Occurrence, intensity and relationship to vaccination of local and general adverse events

    Time frame: 28-day follow-up after rTV vaccination

Secondary outcomes

  1. test HIV specific T cell response by ICS

    Time frame: 4wk, 8wk, 14wk, 48wk after rTV vaccination

  2. HIV neutralizing antibody test

    Time frame: 4wk, 14wk, 48wk after rTV vaccination

  3. vaccinia virus antibody test

    Time frame: 2wk, 4wk, 24wk after rTV vaccination

07

Study locations

1 site
  • Beijing Youan Hospital,Capital Medical University
    Beijing, Beijing, China
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2012, a primary completion of Oct 2014 and a completion of Jan 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2012
First posted
Oct 12, 2012
Start
Aug 2012
Primary completionActual
Oct 2014
CompletionActual
Jan 2015
Last update
May 6, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01705223
Lead sponsor
National Center for AIDS/STD Control and Prevention, China CDC
Responsible party
Sponsor
First posted
Oct 12, 2012
Start date
Aug 2012
Primary completion
Oct 2014
Completion
Jan 2015
Last update
May 6, 2015

Study contacts

Hao Wu, M.D.
principal investigator · Beijing YouAn Hospital
Tong Zhang, M.D.
principal investigator · Beijing YouAn Hospital
Yiming Shao, Ph.D.
principal investigator · NCAIDS, China CDC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vaccines, DNA

Start the discussion